Related Experiment Video
Updated: Apr 20, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
[Added value of clopidogrel in cardiology and neurology]
Freek W A Verheugt1, Geert-Jan Geersing, L Jaap Kappelle
1Onze Lieve Vrouwe Gasthuis, Amsterdam.
Insights
Platelet aggregation inhibitors like acetylsalicylic acid and clopidogrel help prevent cardiovascular events. However, long-term dual therapy increases bleeding risks, especially gastrointestinal bleeding.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Platelet aggregation inhibitors are crucial for managing acute coronary syndromes, TIA, and stroke.
- Acetylsalicylic acid is a cornerstone of secondary prevention.
- Dual therapy with acetylsalicylic acid and ADP receptor antagonists (e.g., clopidogrel) offers potential added benefits.
Purpose of the Study:
- To review current cardiological and neurological uses of platelet inhibition.
- To discuss the risk-benefit profile of dual antiplatelet therapy (DAPT).
- To identify risk factors for severe bleeding events associated with DAPT.
Main Methods:
- Literature review of studies on platelet aggregation inhibitors.
- Analysis of clinical trial data regarding efficacy and safety.
- Examination of risk factors for bleeding complications.
Main Results:
- DAPT is effective in preventing stent thrombosis after percutaneous coronary intervention.
- Long-term DAPT (>1 year) presents an unfavorable risk-benefit ratio, primarily due to increased bleeding, particularly gastric bleeding.
- Combination therapy may benefit TIA/minor stroke patients, but requires further research for patient stratification.
Conclusions:
- Platelet inhibition is vital in cardiovascular and cerebrovascular secondary prevention.
- The duration of DAPT should be carefully considered due to increased bleeding risks.
- Further research is needed to optimize DAPT use in specific patient populations, balancing efficacy and safety.
Abstract:
Platelet aggregation inhibitors reduce the risk of complications during and after acute coronary syndromes and after a TIA or stroke. Acetylsalicylic acid plays a major role in secondary prevention; the combination of acetylsalicylic acid and a platelet ADP receptor antagonist, such as clopidogrel, may have added value. In percutaneous coronary intervention, dual platelet inhibition appears to be effective in the prevention of stent thrombosis. Long-term (> 1 year) use of dual platelet inhibition has an unfavourable risk-benefit profile, partly due to an increase in the number of bleeding events, particularly in the stomach. The use of the combination of acetylsalicylic acid and clopidogrel may be helpful after a TIA or minor stroke, but further research is needed to identify the group of patients for whom this combination would be applicable. This article provides an overview of the modern cardiological and neurological indications for platelet inhibition as well as the risk factors for severe bleeding events when using dual antiplatelet therapy.
More Related Videos
09:21Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Coronary Artery Disease V: Interprofessional Care
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:27Peripheral Artery Disease III: Interprofessional Care
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management